Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
Vivek SubbiahNiamh ColemanSarina A Piha-PaulApostolia-Maria TsimberidouFilip JankuJordi Rodon AhnertShubham PantEcaterina E Ileana DumbravaSiqing FuDavid S HongShizhen ZhangMing SunYunfang JiangJason RoszikJuhee SongYing YuanFunda Meric-BernstamAung NaingPublished in: Cancer research communications (2023)
The safety profile of mTORC1/2 inhibitor sapanisertib in combination with metformin was generally tolerable, with anti-tumor activity observed in patients with advanced malignancies harboring PTEN/ AKT/mTOR pathway alterations.